CMS In Brief
This article was originally published in The Gray Sheet
Executive Summary
MedCAC posts meeting questions: CMS has 1posted a list of voting questions for the Medicare Evidence Development and Coverage Advisory Committee to address during its Sept. 22 meeting on evidence for on- and off-label use of bone morphogenetic proteins. CMS wants feedback on MedCAC's level of confidence that FDA-approved uses of BMPs can improve outcomes related to the lumbar spine, open tibia fractures and recalcitrant long bone nonunion and that off-label use can improve outcomes in the cervical spine, the lumbar spine or elsewhere. The panel will review evidence on BMP products from Medtronic and Stryker. On July 27, an FDA advisory panel had a mixed response to Medtronic's Amplify rhBMP-2 Matrix spinal treatment, currently under PMA review for posterolateral spine fusion
You may also be interested in...
CMS Revisits Coverage Policy For MRI In Patients With Cardiac Implants
In response to a formal request, CMS opened a national coverage analysis June 28 for magnetic resonance imaging of patients with pacemakers or defibrillator implants
Medtronic Hopes For Speedy U.S. Launch Of Revo MRI-Friendly Pacer
Medtronic is hoping to receive FDA approval of its Revo MRI SureScan MRI-safe pacemaker and launch it in the U.S. within six months now that the device has received a unanimous approval recommendation from an FDA advisory panel
CMS Will Cover Warfarin Gene Tests In Clinical Trials, But That's It
Medicare will only cover genetic testing for individual response to the blood-thinner warfarin in the context of controlled clinical studies, effective immediately, CMS said Aug. 3